CRISPR Therapeutics (CRSP)
Develops genome-editing medicines across blood disorders, liver targets, autoimmune disease, and diabetes.
$56.78
vs last close−2.25 (−3.81%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 80.04% | 77.40M shares | |
|---|---|---|---|
| 558 holders · as of Jun 30, 2026 | |||
| Insiders | 0.46% | 445.4K shares | |
| 9 holders · as of Sep 21, 2026 | |||
| Other | 19.50% | 18.85M shares | |
| remainder | |||
96.69M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
558 holders · 77.40M shares · 81 new positions · 236 increased · 149 reduced · 52 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ark Investment Management LLC | 9.46M | 9.78% | −1.85M | Aug 14, 2026 |
| BlackRock, Inc. | 8.35M | 8.63% | +668.9K | Aug 7, 2026 |
| Orbis Allan Gray Ltd | 5.45M | 5.64% | −656.9K | Aug 14, 2026 |
| Capital World Investors | 4.75M | 4.91% | +24.5K | Aug 12, 2026 |
| State Street Corp | 4.32M | 4.47% | +339.2K | Aug 7, 2026 |
| GSK PLC | 3.22M | 3.33% | 0 | Aug 13, 2026 |
| Geode Capital Management, LLC | 2.51M | 2.60% | +132.8K | Aug 12, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.05M | 2.12% | −899.6K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 11.79% | 11.31M | 13G | Apr 30, 2026 |
| BlackRock, Inc. | 6.90% | 5.93M | 13G | Jul 17, 2025 |
| Orbis Investment Management Ltd | 6.30% | 6.09M | 13G | May 15, 2026 |
| Capital World Investors | 5.10% | 4.93M | 13G | May 14, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 17, 2026 | Ali Behbahanidirector | Sale | 13,679 | $57.09 | 16,637 |
| May 29, 2026 | Naimish Patelofficer: Chief Medical Officer | Sale | 3,786 | $55.62 | 19,357 |
| Mar 23, 2026 | Raju Prasadofficer: Chief Financial Officer | Sale | 3,708 | $46.78 | 15,565 |
| Mar 23, 2026 | Samarth Kulkarnidirector, officer: Chief Executive Officer | Sale | 10,020 | $46.78 | 255,501 |
| Mar 23, 2026 | James R. Kasingerofficer: General Counsel and Secretary | Sale | 3,182 | $46.78 | 94,308 |
| Mar 16, 2026 | Samarth Kulkarnidirector, officer: Chief Executive Officer | Sale | 10,349 | $48.26 | 245,834 |
| Mar 16, 2026 | James R. Kasingerofficer: General Counsel and Secretary | Sale | 3,450 | $48.26 | 91,240 |
| Mar 16, 2026 | Raju Prasadofficer: Chief Financial Officer | Sale · 2 lots | 9,869 | $48.26 | 13,773 |
| Mar 16, 2026 | Naimish Patelofficer: Chief Medical Officer | Sale | 3,150 | $48.26 | 13,143 |
| Mar 11, 2026 | Samarth Kulkarnidirector, officer: Chief Executive Officer | Sale | 9,798 | $52.80 | 235,558 |
House and Senate disclosures
Not reported.